You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 130 No. 6, June 2004 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Prognosis/ Outcomes
 •Neoplasms of Head & Neck
 •Pathology of Head & Neck
 •Alert me on articles by topic

Outcome of Patients With Positive Epstein-Barr Virus Serologic Status in the Absence of Nasopharyngeal Carcinoma in Hong Kong

Stephen Lo, BMedSc, MBA, MRCS, DLO; Wai-Kuen Ho, FACS, FRCS(Edin); William I. Wei, MS, FACS, FRCS, FRCS(Edin)

Arch Otolaryngol Head Neck Surg. 2004;130:770-772.

Objective  To evaluate the current clinical practice of follow-up and the outcomes of patients with raised Epstein-Barr virus (EBV) antibody levels but without pathological evidence of nasopharyngeal carcinoma (NPC) for a possible risk of developing NPC in the future.

Design  Retrospective review of prospectively collected database.

Setting  Tertiary referral otorhinolaryngology center.

Patients  The study population comprised 66 patients (27 male and 39 female; median age, 43.5 [range, 9-78] years) who presented in 1997 with a positive EBV IgA viral capsid antigen titer but a negative nasopharyngeal biopsy result.

Main Outcome Measures  The detection of NPC and EBV seroconversion rate.

Results  Of the 66 patients studied, 14 had a positive family history of NPC. Fourteen patients (27%) were excluded because of loss of contact or refusal of follow-up. The median follow-up period of the remaining 52 patients was 54.5 months (range, 12-64 months). Of these 52 patients, 39 (75%) had initial nasendoscopic finding described as completely normal. During the follow-up period, NPC was diagnosed in 1 patient (2%) 18 months after first biopsy. The initial nasendoscopy and histological findings in this patient were normal despite the patient having a raised EBV IgA VCA titer of 1:640. Overall, the EBV serologic status of 36 patients (69%) reverted to normal within the studied period (median interval of 54.5 [range, 12-64] months).

Conclusions  In the median follow-up period of 54.5 months, only 1 patient (2%) developed NPC. A significant proportion of the patients seroconverted back to normal, none of whom developed NPC.


From the Department of Otorhinolaryngology–Head & Neck Surgery, St George's Hospital Medical School, University of London, London, England (Dr Lo); Division of Otorhinolaryngology–Head & Neck Surgery, Department of Surgery, University of Hong Kong Medical Centre, Queen Mary Hospital, Hong Kong (Dr Ho and Dr Wei). The authors have no relevant financial interest in this article.







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.